Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8980562 | 0.83 | LMNA (0.61) | KMT2AMEN1BRD4POLBKDM4E | |
| SCHEMBL13162410 | 0.83 | MEN1 (0.54) | KMT2AMEN1BRD4POLBHPGD | |
| SCHEMBL799166 | 0.82 | KCNK3 (0.53) | KMT2AMEN1KCNK3KCNK9KDM4E | |
| SCHEMBL4828073 | 0.81 | MEN1 (0.53) | KMT2AMEN1BRD4POLBKDM4E | |
| SCHEMBL6387197 | 0.79 | MEN1 (0.50) | KMT2AMEN1BRD4POLBKDM4E | |
| SCHEMBL24480200 | 0.78 | CTSD (0.55) | KMT2AMEN1KCNK3KCNK9LMNA | |
| SCHEMBL15614417 | 0.77 | NLRP3 (0.50) | KMT2AMEN1POLBKCNK3KCNK9 | |
| SCHEMBL24568614 | 0.77 | MEN1 (0.69) | KMT2AMEN1POLBKDM4EHPGD | |
| SCHEMBL3380039 | 0.77 | RAB9A (0.65) | KMT2AMEN1HPGDLMNAALDH1A1 | |
| SCHEMBL12019757 | 0.77 | RAB9A (0.65) | KMT2AMEN1HPGDLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KMT2A 2921/4885MEN1 2694/4885BRD4 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.